Jeff Sevigny

4.1k total citations
11 papers, 355 citations indexed

About

Jeff Sevigny is a scholar working on Physiology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jeff Sevigny has authored 11 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Physiology, 3 papers in Molecular Biology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jeff Sevigny's work include Alzheimer's disease research and treatments (4 papers), Medical Imaging Techniques and Applications (3 papers) and Dementia and Cognitive Impairment Research (2 papers). Jeff Sevigny is often cited by papers focused on Alzheimer's disease research and treatments (4 papers), Medical Imaging Techniques and Applications (3 papers) and Dementia and Cognitive Impairment Research (2 papers). Jeff Sevigny collaborates with scholars based in United States, Switzerland and Australia. Jeff Sevigny's co-authors include Leslie Williams, John O’Gorman, J L Ferrero, Alvydas Mikulskis, Ping Chiao, Tianle Chen, Mehul Sampat, Jerome Barakos, Derk D. Purcell and Joonmi Oh and has published in prestigious journals such as SHILAP Revista de lepidopterología, Science Translational Medicine and Alzheimer s & Dementia.

In The Last Decade

Jeff Sevigny

11 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeff Sevigny United States 6 191 129 107 65 53 11 355
Daniel D. Christensen United States 13 84 0.4× 94 0.7× 89 0.8× 58 0.9× 27 0.5× 21 315
Kazuto Oya Japan 11 83 0.4× 205 1.6× 106 1.0× 45 0.7× 16 0.3× 15 462
Jay C. Kwon South Korea 10 114 0.6× 161 1.2× 59 0.6× 91 1.4× 23 0.4× 24 406
Hana Florian United States 8 203 1.1× 219 1.7× 256 2.4× 97 1.5× 47 0.9× 20 502
Amber M. Tetlow United States 6 132 0.7× 77 0.6× 46 0.4× 75 1.2× 23 0.4× 13 361
Marie‐Laure Rouzade‐Dominguez United States 8 127 0.7× 51 0.4× 63 0.6× 19 0.3× 43 0.8× 16 380
Van Dang United States 7 118 0.6× 53 0.4× 55 0.5× 50 0.8× 12 0.2× 10 328
H. Gerbaldo Germany 10 146 0.8× 152 1.2× 57 0.5× 47 0.7× 20 0.4× 21 407
Cristina López López Switzerland 10 141 0.7× 190 1.5× 58 0.5× 13 0.2× 29 0.5× 18 329
S. Cammarata Italy 9 226 1.2× 90 0.7× 53 0.5× 14 0.2× 33 0.6× 13 451

Countries citing papers authored by Jeff Sevigny

Since Specialization
Citations

This map shows the geographic impact of Jeff Sevigny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Sevigny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Sevigny more than expected).

Fields of papers citing papers by Jeff Sevigny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Sevigny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Sevigny. The network helps show where Jeff Sevigny may publish in the future.

Co-authorship network of co-authors of Jeff Sevigny

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Sevigny. A scholar is included among the top collaborators of Jeff Sevigny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Sevigny. Jeff Sevigny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Umbricht, Daniel, Markus Abt, Christopher H. Chatham, et al.. (2021). Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms. SHILAP Revista de lepidopterología. 1(1). 70–77. 9 indexed citations
2.
Bolognani, Federico, Marta del Valle Rubido, Lisa Squassante, et al.. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine. 11(491). 75 indexed citations
3.
Sevigny, Jeff, Joyce Suhy, Ping Chiao, et al.. (2016). Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials. Alzheimer Disease & Associated Disorders. 30(1). 1–7. 86 indexed citations
4.
Ferrero, J L, et al.. (2016). First‐in‐human, double‐blind, placebo‐controlled, single‐dose escalation study of aducanumab (BIIB037) in mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 2(3). 169–176. 132 indexed citations
5.
6.
Bedell, Barry J., Félix Carbonell, Arnaud Charil, et al.. (2014). P3‐212: OPTIMIZED, FULLY‐AUTOMATED CLASSIFICATION OF AMYLOID‐POSITIVE SUBJECTS BASED ON [18F]FLORBETAPIR PET SCANS. Alzheimer s & Dementia. 10(4S_Part_19). 1 indexed citations
7.
Chiao, Ping, Joyce Suhy, Jerome Barakos, et al.. (2014). O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS. Alzheimer s & Dementia. 10(4S_Part_4). 1 indexed citations
8.
Klein, Gregory, Ping Chiao, Jerome Barakos, et al.. (2014). P1‐252: CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS. Alzheimer s & Dementia. 10(4S_Part_10). 2 indexed citations
9.
10.
Sheng, Zhifeng, Jeff Sevigny, Ajay Verma, et al.. (2013). P1–071: Genetic and imaging biomarkers predicting beta‐amyloid amyloid–related cognitive decline using the Alzheimer's Disease Neuroimaging Initiative data. Alzheimer s & Dementia. 9(4S_Part_4). 2 indexed citations
11.
Lee, Jae‐Hong & Jeff Sevigny. (2010). Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch. Alzheimer Disease & Associated Disorders. 25(1). 58–62. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel D. Christensen Breakdown of academic impact, for papers by Kazuto Oya Breakdown of academic impact, for papers by Jay C. Kwon Breakdown of academic impact, for papers by Hana Florian Breakdown of academic impact, for papers by Amber M. Tetlow Breakdown of academic impact, for papers by Marie‐Laure Rouzade‐Dominguez Breakdown of academic impact, for papers by Van Dang Breakdown of academic impact, for papers by H. Gerbaldo Breakdown of academic impact, for papers by Cristina López López Breakdown of academic impact, for papers by S. Cammarata
Rankless by CCL
2026